

Chondroprotective Effects of Avocado/Soybean Unsaponifiables Versus Glucosamine–Chondroitin Sulfate: A Comprehensive Review of Preclinical and Clinical Evidence

Ibrahim Ali Awwad¹, Elsayed Mohammed Kamel², Alaa Nasr Abdelwahab Mohamed³, Zeinab Mahmoud Saeed⁴

1. Assistant Professor of Clinical Pharmacology, Faculty of Medicine - Zagazig University,
 2. Professor of Clinical Pharmacology, Faculty of Medicine - Zagazig University,
 3. Demonstrator of Clinical Pharmacology, Faculty of Medicine - Zagazig University,
 4. Lecturer of Clinical Pharmacology, Faculty of Medicine - Zagazig University
- Corresponding author: Alaa Nasr Abdelwahab Mohamed

Received: 13 March 2024, **Accepted:** 17 April 2024, **Published:** 20 May 2024

ABSTRACT

Background: Osteoarthritis (OA) is the most prevalent degenerative joint disorder, characterized by progressive loss of articular cartilage, subchondral bone remodeling, synovial inflammation, and chronic pain. Conventional pharmacological options, including nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, primarily target symptoms but fail to halt or reverse cartilage degradation, often resulting in adverse effects with long-term use. Nutraceuticals such as glucosamine and chondroitin sulfate have been widely investigated as disease-modifying osteoarthritis drugs (DMOADs), with evidence suggesting moderate symptomatic relief and potential structural benefits. More recently, avocado/soybean unsaponifiables (ASU), a natural extract comprising one-third avocado and two-thirds soybean oil, have emerged as a promising chondroprotective agent with anti-inflammatory, anabolic, and anticatabolic properties. Preclinical studies and clinical trials have indicated that ASU may modulate cartilage metabolism, reduce pro-inflammatory mediators, and enhance extracellular matrix synthesis, providing a complementary or alternative therapeutic strategy for OA management. This review aims to critically evaluate and compare the chondroprotective efficacy of avocado/soybean unsaponifiables with that of the established glucosamine–chondroitin sulfate combination. By synthesizing evidence from preclinical models and clinical trials, we explore their mechanisms of action, therapeutic outcomes on cartilage integrity, pain reduction, functional improvement, and safety profiles. Particular emphasis is placed on the differential modulation of inflammatory pathways, matrix metalloproteinase activity, and structural progression of OA.

Conclusion: Evidence suggests that both ASU and glucosamine–chondroitin exert beneficial effects in the management of OA, with potential disease-modifying properties beyond symptom control. Glucosamine–chondroitin remains the most extensively studied nutraceutical combination, with documented clinical efficacy in reducing pain and improving joint function, though variability in study quality and patient response limits universal recommendations. ASU, by contrast, has demonstrated robust chondroprotective and anti-inflammatory activity in preclinical research and encouraging clinical trial outcomes, particularly in slowing joint space narrowing and reducing NSAID dependence. While comparative head-to-head trials remain limited, emerging data suggest that ASU may offer equivalent or even superior benefits in terms of structural preservation and long-term safety. Further large-scale, standardized clinical studies are warranted to establish optimal dosing regimens, long-term efficacy, and potential synergistic use of these nutraceuticals.

Keywords: Chondroprotective Effects, Glucosamine–Chondroitin Sulfate ,Comprehensive Review

INTRODUCTION

Osteoarthritis (OA) is the most common musculoskeletal disorder, affecting over 500 million people worldwide, and represents a leading cause of disability among older adults. Clinically, it is characterized by progressive articular cartilage loss, synovial inflammation, osteophyte formation, and subchondral bone sclerosis, ultimately impairing mobility and quality of life. Current therapeutic approaches—including acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), intra-articular corticosteroids, and hyaluronic acid—provide symptomatic relief but do not alter the underlying disease progression. Long-term use of these agents is associated with gastrointestinal, cardiovascular, renal, and metabolic complications, highlighting the urgent need for safer disease-modifying strategies [1,2].

Glucosamine and chondroitin sulfate are among the most widely studied nutraceuticals in OA management. They are natural components of cartilage extracellular matrix and have been proposed to restore cartilage integrity, inhibit inflammatory mediators, and provide pain relief. Several randomized controlled trials (RCTs) have demonstrated improvements in pain scores, joint function, and structural outcomes such as joint space width, though results remain inconsistent across populations and formulations [3,4]. Despite controversy, many clinical guidelines recognize glucosamine–chondroitin as an adjunct or alternative for patients intolerant to NSAIDs.

In parallel, avocado/soybean unsaponifiables (ASU), an extract composed of one-third avocado oil and two-thirds soybean oil, have gained attention for their chondroprotective and anti-inflammatory properties. ASU modulates multiple pathways, including inhibition of pro-inflammatory cytokines (IL-1 β , TNF- α), downregulation of matrix metalloproteinases (MMPs), and stimulation of anabolic processes such as collagen and aggrecan synthesis. Both in vitro and in vivo models support its disease-modifying potential, and clinical studies have demonstrated symptomatic improvement, reduced NSAID consumption, and possible delay in structural progression [5,6].

From a clinical pharmacy perspective, the comparative evaluation of ASU versus glucosamine–chondroitin sulfate is crucial to guide evidence-based therapeutic decisions. Pharmacists play an essential role in evaluating the safety, efficacy, and cost-effectiveness of nutraceuticals, particularly given their widespread over-the-counter availability and frequent use in self-medication. Moreover, understanding pharmacodynamic differences, onset of action, drug–nutrient interactions, and adherence patterns is vital to optimize outcomes in OA patients.

The objective of this review is therefore to provide a comprehensive synthesis of preclinical and clinical evidence comparing the chondroprotective effects of avocado/soybean unsaponifiables and glucosamine–chondroitin sulfate. By critically analyzing their mechanisms, therapeutic outcomes, safety, and role in current treatment algorithms, this work aims to define their position within evidence-based OA management and identify gaps for future research.

1. Epidemiology and Burden of Osteoarthritis

Osteoarthritis (OA) is the most prevalent joint disorder globally, affecting more than 500 million people and ranking among the leading causes of years lived with disability. Its prevalence rises sharply with age, with nearly one in three adults over 65 years demonstrating radiographic evidence of OA, and symptomatic disease being particularly common in weight-bearing joints such as the knee and hip. From a healthcare perspective, OA imposes significant challenges due to its chronicity, high prevalence, and lack of curative therapies [7].

The economic burden of OA is profound, encompassing both direct and indirect costs. Direct costs arise from physician visits, imaging, pharmacological and surgical treatments, and rehabilitation services. Indirect costs include work absenteeism, early retirement, and decreased productivity, which can exceed the direct medical expenses in working-age populations. Estimates suggest that OA accounts for up to 2% of the gross domestic product in some high-income countries, highlighting the magnitude of its societal impact [8].

OA not only affects physical health but also exerts considerable psychosocial burden. Patients frequently report limitations in activities of daily living, social withdrawal, depression, and reduced overall quality of life. Pain, stiffness, and functional decline contribute to sleep disturbances and fatigue, exacerbating disability. The chronic and progressive nature of OA creates a cycle of reduced mobility and worsening comorbidities such as obesity, diabetes, and cardiovascular disease, further complicating disease management [9].

Importantly, the global epidemiology of OA is influenced by modifiable risk factors, such as obesity, occupational stress on joints, and sedentary lifestyle. Rising obesity rates are particularly concerning, as each unit increase in body mass index (BMI) significantly elevates the risk of knee OA. This epidemiological trend underscores the importance of preventive strategies, including weight management, physical activity promotion, and early pharmacological intervention in high-risk populations [10].

In summary, OA represents a major public health concern with wide-ranging consequences for patients, caregivers, and health systems. Understanding its epidemiology and burden provides the foundation for evaluating new therapeutic options, including nutraceuticals such as glucosamine–chondroitin and avocado/soybean unsaponifiables, which may offer safer and more sustainable approaches for long-term management [11].

2. Pathophysiology of Osteoarthritis

Osteoarthritis (OA) is no longer viewed as a purely “wear-and-tear” disease but rather as a complex disorder involving mechanical, inflammatory, and biochemical pathways. At its core, OA results from an imbalance between catabolic processes that degrade cartilage and anabolic processes that repair and maintain joint integrity. Chondrocytes, the only cellular component of articular cartilage, attempt to compensate for extracellular matrix (ECM) loss but eventually become senescent and unable to restore homeostasis. This dynamic imbalance leads to progressive cartilage erosion and symptomatic joint degeneration [12].

A hallmark of OA pathology is the increased production of pro-inflammatory cytokines such as interleukin-1 beta (IL-1 β), tumor necrosis factor-alpha (TNF- α), and interleukin-6 (IL-6). These mediators activate downstream signaling pathways including nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B), resulting in upregulation of matrix metalloproteinases (MMPs) and aggrecanases. MMP-3, MMP-13, and ADAMTS-5 are particularly destructive, breaking down type II collagen and aggrecan, which are essential for cartilage strength and elasticity [13].

In addition to inflammation, subchondral bone remodeling plays a central role in OA. Mechanical stress and microfractures trigger osteoblast and osteoclast activity, leading to sclerosis and osteophyte formation. This structural remodeling alters joint biomechanics and perpetuates cartilage damage. Moreover, angiogenesis and nerve infiltration into the normally aneural and avascular cartilage contribute to pain sensitization and chronicity of symptoms [14].

Synovial inflammation, or synovitis, further accelerates disease progression. Synovial fibroblasts produce inflammatory mediators and degradative enzymes, sustaining a pro-catabolic microenvironment. Macrophage infiltration into the synovium amplifies cytokine release and oxidative stress, thereby intensifying joint damage. Importantly, synovitis has been correlated with pain severity, making it a key therapeutic target [15].

Recent studies highlight the role of metabolic factors in OA pathophysiology, particularly in obese patients. Adipose tissue secretes adipokines such as leptin, adiponectin, and resistin, which can modulate cartilage metabolism and inflammation. This emerging understanding positions OA not only as a mechanical disease but also as a metabolic and systemic disorder, reinforcing the need for therapies that address inflammation and matrix integrity simultaneously [16].

From a clinical pharmacy perspective, these mechanistic insights justify the exploration of nutraceuticals such as glucosamine, chondroitin, and avocado/soybean unsaponifiables. By modulating cytokine release, suppressing MMP activity, and promoting ECM synthesis, these agents directly target the biological processes underlying OA rather than simply alleviating symptoms. This differentiates them from conventional analgesics and underscores their potential disease-modifying role [17].

3. Limitations of Conventional Pharmacotherapy

The current pharmacological management of osteoarthritis (OA) is primarily focused on symptomatic relief rather than disease modification. The most commonly used agents are nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and intra-articular corticosteroids. While these therapies provide short-term improvements in pain and function, none of them halt or reverse cartilage degradation, highlighting a major therapeutic gap. This symptomatic approach leaves patients vulnerable to long-term disease progression and eventual surgical interventions such as joint replacement [18].

NSAIDs remain the cornerstone of pharmacotherapy for OA, given their ability to inhibit cyclooxygenase (COX) enzymes and reduce prostaglandin-mediated inflammation. However, their prolonged use is associated with gastrointestinal ulceration, bleeding, renal dysfunction, and increased cardiovascular risk. Selective COX-2 inhibitors, though safer for the gastrointestinal tract, carry a higher risk of myocardial infarction and stroke. These safety concerns limit their long-term use, especially in elderly patients who often present with multiple comorbidities [19].

Acetaminophen is frequently recommended as a first-line analgesic due to its favorable safety profile compared to NSAIDs. However, its analgesic efficacy in OA is modest, and recent meta-analyses question its clinical relevance in managing moderate-to-severe OA pain. Moreover, chronic high-dose use carries the risk of hepatotoxicity, particularly in patients with underlying liver disease or concomitant alcohol consumption. This limited efficacy positions acetaminophen as a suboptimal long-term solution for OA symptom management [20].

Intra-articular corticosteroids are often employed to manage acute exacerbations of pain and inflammation. Although they can provide rapid relief, the effects are transient, typically lasting four to six weeks. Repeated injections are discouraged due to potential adverse effects, including cartilage deterioration and increased risk of joint infection. Their role is therefore restricted to short-term crisis management rather than sustained therapy [21].

Hyaluronic acid injections, another intra-articular option, aim to restore viscoelasticity of synovial fluid and provide lubrication. Clinical evidence, however, remains inconsistent, with some trials demonstrating marginal improvements in pain and function while others show no superiority over placebo. Furthermore, the cost and need for repeated injections limit their accessibility in routine clinical practice [22].

From a clinical pharmacy standpoint, these limitations highlight an unmet need for safe, effective, and long-term disease-modifying alternatives. The adverse effect profiles of NSAIDs and corticosteroids, the questionable efficacy of acetaminophen, and the variability of intra-articular therapies leave a large patient population inadequately managed. This scenario has driven interest toward nutraceuticals like

glucosamine, chondroitin, and avocado/soybean unsaponifiables, which may offer safer, multi-targeted chondroprotective effects with fewer systemic risks [23].

4. Nutraceuticals in Osteoarthritis Management

Nutraceuticals have emerged as promising alternatives in osteoarthritis (OA) management because they target underlying pathophysiological mechanisms rather than solely alleviating pain. The most extensively studied agents are glucosamine, chondroitin sulfate, and avocado/soybean unsaponifiables (ASU). Unlike NSAIDs or corticosteroids, nutraceuticals are generally well tolerated, safe for long-term administration, and possess the potential to slow disease progression by modulating cartilage metabolism. These features make them particularly appealing for patients requiring lifelong therapy [24].

Glucosamine and chondroitin sulfate, both naturally occurring components of the cartilage extracellular matrix, have been widely marketed as over-the-counter supplements. Their use is supported by biological plausibility: glucosamine serves as a substrate for glycosaminoglycan synthesis, while chondroitin provides structural integrity to cartilage. Numerous preclinical studies demonstrate their anti-catabolic effects, including inhibition of matrix metalloproteinases (MMPs), suppression of pro-inflammatory cytokines, and promotion of proteoglycan synthesis. However, clinical results have been inconsistent, with variability in study design, patient populations, and supplement quality complicating interpretation [25].

Avocado/soybean unsaponifiables represent a newer category of nutraceuticals gaining attention in OA research. ASU is a natural extract composed of phytosterols, tocopherols, and fat-soluble compounds derived from one-third avocado oil and two-thirds soybean oil. Evidence indicates that ASU exerts a dual action: inhibiting pro-inflammatory cytokines such as interleukin-1 beta (IL-1 β) and tumor necrosis factor-alpha (TNF- α), while enhancing anabolic processes like collagen and aggrecan synthesis. This unique profile positions ASU as both an anti-inflammatory and chondroprotective agent, offering a potentially superior disease-modifying effect compared to traditional nutraceuticals [26].

Another aspect enhancing the appeal of nutraceuticals is their role in reducing reliance on NSAIDs. Clinical trials have demonstrated that patients receiving glucosamine, chondroitin, or ASU often report decreased NSAID consumption, which is clinically significant given the adverse effect profile of NSAIDs in elderly, comorbid populations. By offering both symptom relief and structural benefits, nutraceuticals align with the clinical pharmacy goal of optimizing safety, efficacy, and adherence in long-term therapy [27].

Despite their promise, nutraceuticals face regulatory and quality-control challenges. Over-the-counter formulations vary widely in purity, bioavailability, and dosage strength, which may explain the heterogeneity in trial outcomes. Pharmaceutical-grade glucosamine sulfate, for example, appears to

provide more consistent benefits than dietary supplement formulations. For ASU, standardization of extraction methods is critical to ensuring reproducible efficacy. From a pharmacist's perspective, guiding patients toward evidence-based, pharmaceutical-grade preparations is essential to achieving therapeutic benefit [28].

In conclusion, nutraceuticals occupy an increasingly important role in OA management. They offer safe, long-term therapy options that may alter disease progression, especially when initiated in early stages of OA. The comparison of ASU versus glucosamine–chondroitin sulfate is particularly relevant, as these agents represent the two most promising categories of nutraceuticals with disease-modifying potential. Understanding their mechanisms, evidence base, and limitations is crucial for integrating them into clinical practice [29].

5. Mechanism of Action of Glucosamine

Glucosamine is a naturally occurring amino-monosaccharide and a fundamental building block in the biosynthesis of glycosaminoglycans (GAGs), which are critical components of articular cartilage and synovial fluid. In osteoarthritis (OA), the loss of proteoglycans compromises the mechanical resilience of cartilage, leading to progressive degeneration. Supplementation with glucosamine is proposed to replenish substrates necessary for GAG synthesis, thereby supporting cartilage repair and maintenance. This anabolic effect directly addresses one of the core deficiencies in OA pathophysiology [30].

Beyond serving as a structural substrate, glucosamine exerts several pharmacological effects relevant to chondroprotection. Preclinical studies have shown that glucosamine inhibits interleukin-1 beta (IL-1 β)-induced activation of nuclear factor kappa B (NF- κ B), a transcription factor responsible for upregulating pro-inflammatory cytokines and matrix metalloproteinases (MMPs). By attenuating NF- κ B signaling, glucosamine reduces the expression of degradative enzymes such as MMP-3 and MMP-13, thereby slowing extracellular matrix breakdown. This anti-inflammatory action highlights glucosamine's role not only in structural support but also in modulating inflammatory pathways [31].

Glucosamine also influences oxidative stress, which contributes to chondrocyte apoptosis in OA. Experimental data suggest that glucosamine enhances antioxidant defenses by upregulating superoxide dismutase and glutathione peroxidase activity, while reducing reactive oxygen species accumulation. By preserving chondrocyte viability and preventing apoptosis, glucosamine helps maintain the cellular machinery required for matrix repair. These cytoprotective properties add another dimension to its therapeutic potential [32].

From a pharmacokinetic perspective, glucosamine is absorbed in the gastrointestinal tract, though oral bioavailability varies depending on the salt form. Glucosamine sulfate, particularly in stabilized crystalline formulations, demonstrates higher and more consistent bioavailability than glucosamine hydrochloride. Clinical evidence indicates that only pharmaceutical-grade glucosamine sulfate has reliably shown efficacy in randomized controlled trials, underscoring the importance of formulation

quality in determining therapeutic outcomes. This distinction is critical for pharmacists when advising patients on supplement selection [33].

An additional mechanism that has gained attention is glucosamine's potential to modulate epigenetic and metabolic processes. Recent studies indicate that glucosamine may inhibit O-linked N-acetylglucosamine transferase (OGT) activity, thereby influencing protein glycosylation and gene transcription. This effect could alter inflammatory gene expression in synovial tissues. While this area remains under investigation, it underscores glucosamine's capacity to exert pleiotropic actions beyond cartilage metabolism [34].

Taken together, glucosamine exerts its chondroprotective activity through multiple mechanisms: provision of anabolic substrates for cartilage repair, inhibition of pro-inflammatory signaling, reduction of oxidative stress, and possible modulation of gene expression. These multifaceted actions provide a strong biological rationale for its use in OA management, particularly when combined with chondroitin sulfate for synergistic effects. From a clinical pharmacy standpoint, the evidence highlights the importance of product standardization and dosing consistency in translating mechanistic benefits into meaningful clinical outcomes [35].

6. Mechanism of Action of Chondroitin Sulfate

Chondroitin sulfate (CS) is a sulfated glycosaminoglycan naturally present in the extracellular matrix of articular cartilage, where it provides structural support and elasticity. It binds with proteins to form proteoglycans such as aggrecan, which are essential for cartilage hydration and resistance to compressive forces. In osteoarthritis (OA), degradation of chondroitin-rich proteoglycans results in loss of cartilage resilience and joint space narrowing. Oral supplementation with CS aims to restore these structural deficits by supplying precursors for proteoglycan synthesis [36].

One of the most critical actions of CS is its ability to downregulate catabolic enzymes responsible for cartilage breakdown. Studies have shown that CS reduces the activity of matrix metalloproteinases (MMP-1, MMP-3, and MMP-13) and aggrecanases such as ADAMTS-4 and ADAMTS-5. By inhibiting these degradative enzymes, CS helps preserve type II collagen and aggrecan, two key components of the cartilage extracellular matrix. This mechanism distinguishes CS from purely symptomatic agents, positioning it as a potential disease-modifying therapy [37].

CS also exhibits anti-inflammatory activity by modulating cytokine production. It has been shown to inhibit interleukin-1 beta (IL-1 β)-induced synthesis of prostaglandin E2 (PGE2) and nitric oxide (NO) in chondrocytes, thereby reducing local inflammation. Furthermore, CS interferes with nuclear factor kappa B (NF- κ B) signaling, a master regulator of inflammatory gene expression. This action contributes to decreased synovial inflammation, which is directly linked to OA pain and progression [38].

Beyond its effects on cartilage, CS influences subchondral bone metabolism. OA is characterized not only by cartilage degeneration but also by pathological changes in underlying bone, such as sclerosis and osteophyte formation. Preclinical studies suggest that CS reduces osteoclast activity and enhances osteoblast differentiation, leading to improved bone remodeling. This dual action on both cartilage and bone further underscores CS's disease-modifying potential [39].

Pharmacokinetic studies indicate that orally administered CS is absorbed and distributed to joint tissues, albeit with relatively low bioavailability compared to small molecules. Interestingly, CS fragments generated during digestion may retain biological activity and reach the synovium and cartilage in therapeutic concentrations. Although the exact mechanism of tissue targeting remains under investigation, clinical benefits observed in randomized controlled trials support its pharmacological relevance [40].

From a clinical pharmacy perspective, the quality of CS formulations is crucial. Pharmaceutical-grade CS has demonstrated superior outcomes compared to food supplement-grade preparations, likely due to differences in purity, molecular weight, and bioavailability. Standardization of molecular weight appears particularly important, as low-molecular-weight CS may penetrate cartilage more effectively. Pharmacists play a pivotal role in guiding patients toward evidence-based formulations to ensure therapeutic efficacy [41].

In summary, CS acts through multiple complementary mechanisms: replenishment of proteoglycan precursors, inhibition of catabolic enzymes, modulation of inflammatory pathways, and regulation of bone remodeling. These combined effects provide strong biological plausibility for its role in OA therapy. When integrated into clinical management, CS offers both symptomatic relief and structural protection, particularly when used alongside glucosamine for synergistic benefits [42].

7. Synergistic Effects of Glucosamine–Chondroitin

The combination of glucosamine and chondroitin sulfate has been widely studied due to their complementary mechanisms of action on cartilage metabolism. Glucosamine primarily supports anabolic processes by providing the substrate for glycosaminoglycan synthesis, while chondroitin sulfate inhibits catabolic enzymes and modulates inflammation. When used together, these agents exert a dual effect: enhancing extracellular matrix synthesis and preventing its degradation. This synergy is especially relevant in osteoarthritis (OA), where the imbalance between anabolic and catabolic processes drives disease progression [43].

Clinical evidence supports the hypothesis that the glucosamine–chondroitin combination may provide superior efficacy compared to either agent alone. The Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT), a large randomized controlled study, evaluated the effects of the combination in patients with knee OA. While the overall population did not show statistically significant benefit compared to placebo, a subgroup analysis revealed that patients with moderate-to-severe pain experienced clinically

meaningful improvement. This suggests that the combination may be particularly effective in advanced or symptomatic disease states [44].

Beyond pain relief, long-term studies indicate that glucosamine–chondroitin may influence structural progression of OA. Data from European trials demonstrate that patients receiving the combination exhibit reduced joint space narrowing over three years, suggesting a disease-modifying effect. These findings align with preclinical data showing that the combination reduces expression of matrix metalloproteinases (MMPs), stimulates type II collagen synthesis, and enhances proteoglycan deposition within cartilage. Importantly, these benefits appear to require consistent, long-term administration, highlighting the need for patient adherence [45].

Another important aspect of the glucosamine–chondroitin combination is its impact on safety and tolerability compared to conventional drugs. Both agents are generally well tolerated, with mild gastrointestinal disturbances being the most commonly reported adverse effects. Unlike NSAIDs, they do not increase the risk of cardiovascular or renal complications. From a clinical pharmacy standpoint, this makes the combination attractive for elderly patients or those with comorbid conditions who cannot tolerate chronic NSAID therapy [46].

Despite encouraging evidence, the glucosamine–chondroitin combination has been subject to controversy due to variability in study outcomes. Differences in the purity, formulation, and bioavailability of supplements significantly affect efficacy. Pharmaceutical-grade crystalline glucosamine sulfate and highly purified chondroitin sulfate consistently demonstrate clinical benefit, whereas food supplement-grade products show inconsistent results. This underscores the pharmacist's role in ensuring that patients select evidence-based, pharmaceutical-grade formulations to achieve meaningful therapeutic outcomes [47].

In conclusion, the synergistic use of glucosamine and chondroitin represents a rational strategy for OA management, with evidence supporting both symptomatic relief and structural preservation in select patient populations. While heterogeneity in study results has generated debate, the weight of high-quality evidence suggests a role for the combination in moderate-to-severe OA, particularly when pharmaceutical-grade products are used and adherence is maintained [48].

8. Mechanism of Action of Avocado/Soybean Unsaponifiables (ASU)

Avocado/soybean unsaponifiables (ASU) are natural extracts composed of approximately one-third avocado oil and two-thirds soybean oil. The “unsaponifiable” fraction refers to the lipid components that remain after saponification, including phytosterols, tocopherols, fat-soluble vitamins, and other bioactive lipids. These compounds collectively exert anti-inflammatory, anabolic, and chondroprotective effects that are highly relevant to osteoarthritis (OA) management. Unlike conventional analgesics, ASU targets multiple biological pathways implicated in cartilage destruction and joint inflammation [49].

One of the primary mechanisms of ASU is inhibition of pro-inflammatory cytokines, particularly interleukin-1 beta (IL-1 β), tumor necrosis factor-alpha (TNF- α), and interleukin-6 (IL-6). These cytokines activate nuclear factor kappa B (NF- κ B), a transcription factor that upregulates matrix metalloproteinases (MMPs) and aggrecanases, leading to cartilage degradation. Experimental studies show that ASU downregulates NF- κ B signaling, thereby suppressing the production of MMP-3, MMP-13, and ADAMTS-5. This reduction in catabolic enzyme activity directly contributes to preservation of type II collagen and aggrecan within articular cartilage [50].

In addition to anti-catabolic effects, ASU stimulates anabolic pathways in chondrocytes. Specifically, it enhances the expression of transforming growth factor-beta (TGF- β) and insulin-like growth factor-1 (IGF-1), which promote synthesis of proteoglycans and collagen. This dual activity—suppressing cartilage breakdown while enhancing repair—distinguishes ASU as a disease-modifying nutraceutical rather than merely a symptomatic therapy. In vitro studies have further demonstrated that ASU enhances aggrecan gene expression, leading to improved cartilage resilience and biomechanical function [51].

ASU also influences synovial inflammation, which is a major contributor to OA pain. Synovial fibroblasts exposed to ASU demonstrate reduced secretion of inflammatory mediators such as prostaglandin E2 (PGE2) and nitric oxide (NO). By modulating synovial inflammation, ASU indirectly reduces pain and swelling while protecting the intra-articular environment from further damage. This mechanism explains clinical findings that ASU reduces dependency on NSAIDs, as patients often experience improved joint comfort with sustained supplementation [52].

Another important mechanism is ASU's effect on subchondral bone metabolism. OA progression is associated with abnormal bone remodeling, characterized by osteoblast hyperactivity and osteophyte formation. Preclinical studies have shown that ASU modulates osteoblast and osteoclast activity, reducing osteophyte development and improving subchondral bone quality. This activity provides additional structural benefits, complementing its effects on cartilage and synovium [53].

From a clinical pharmacy perspective, ASU's multimodal mechanisms make it a particularly promising candidate for disease modification in OA. Unlike glucosamine and chondroitin, which primarily act on cartilage metabolism, ASU exerts broader effects that encompass cartilage, synovium, and subchondral bone. This "whole joint" activity aligns with the current understanding of OA as a disease of the entire joint organ rather than cartilage alone. Its pleiotropic actions support the rationale for integrating ASU into therapeutic regimens, especially for patients with progressive or refractory OA [54].

9. Preclinical Evidence for ASU

Preclinical studies have provided a strong scientific basis for the use of avocado/soybean unsaponifiables (ASU) in osteoarthritis (OA). Early investigations in animal models demonstrated that

ASU reduced cartilage degradation and improved histological scores. In surgically induced OA models in rabbits, ASU supplementation significantly decreased cartilage fibrillation and erosion compared to untreated controls. These protective effects were accompanied by improvements in subchondral bone architecture, underscoring the multi-tissue activity of ASU within the joint [55].

In vitro experiments using cultured human chondrocytes have shown that ASU suppresses the catabolic effects of interleukin-1 beta (IL-1 β). Specifically, ASU downregulates matrix metalloproteinase (MMP) expression, particularly MMP-3 and MMP-13, and reduces nitric oxide and prostaglandin E2 production. This suggests that ASU can directly counteract inflammatory signaling cascades that drive cartilage destruction. At the same time, ASU enhances anabolic activity by upregulating transforming growth factor-beta (TGF- β) and collagen type II expression, supporting cartilage repair [56].

Other preclinical studies have highlighted ASU's ability to protect synovial tissues. In cultures of synoviocytes, ASU reduced the secretion of pro-inflammatory cytokines such as TNF- α and IL-6, while decreasing cyclooxygenase-2 (COX-2) expression. These effects are clinically relevant because synovitis is closely linked to OA pain and progression. By targeting synovial inflammation, ASU demonstrates a mechanism of action distinct from purely cartilage-directed therapies such as glucosamine and chondroitin [57].

In canine models of OA, long-term ASU administration delayed disease progression and improved mobility scores. Histological analysis revealed decreased osteophyte formation and reduced synovial hyperplasia. Furthermore, ASU-treated animals required fewer NSAIDs to maintain mobility, which mirrors findings from human clinical trials. This highlights the translational potential of preclinical findings to clinical practice, particularly regarding its NSAID-sparing effect [58].

Molecular studies have also identified that ASU may influence bone remodeling processes. In osteoblast cultures derived from subchondral bone of OA patients, ASU reduced abnormal production of pro-resorptive mediators, thereby normalizing bone turnover. This dual effect on cartilage and bone provides further justification for ASU as a whole-joint therapy, aligning with the modern understanding of OA as a multi-tissue disease rather than solely a cartilage disorder [59].

From a clinical pharmacy perspective, preclinical evidence emphasizes ASU's potential as a multi-targeted therapy capable of modifying OA progression. By acting at the levels of cartilage, synovium, and subchondral bone, ASU addresses multiple aspects of joint pathology. This distinguishes it from conventional pharmacotherapy and supports its consideration as a complementary or alternative therapy in long-term OA management [60].

10. Clinical Evidence for ASU

Clinical studies have consistently demonstrated that avocado/soybean unsaponifiables (ASU) provide symptomatic relief and potential disease-modifying effects in patients with osteoarthritis (OA). Randomized controlled trials (RCTs) have shown significant improvements in pain scores, mobility,

and functional outcomes when ASU is administered over prolonged periods. One of the most notable findings is its ability to reduce the need for concomitant NSAIDs, which represents an important clinical advantage given the long-term toxicity profile of these agents [61].

A pivotal three-year double-blind RCT by Maheu and colleagues investigated the impact of ASU on hip OA. Patients receiving 300 mg of ASU daily demonstrated significantly less joint space narrowing compared to placebo, suggesting a structural protective effect. Additionally, ASU-treated patients reported improvements in Lequesne's functional index and reduced dependence on analgesics. These findings provide strong evidence that ASU not only alleviates symptoms but also delays disease progression, a key goal in OA management [62].

Similar benefits have been observed in knee OA. In a multicenter RCT involving over 160 patients, ASU supplementation resulted in significant improvements in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and function scores compared to placebo. Importantly, patients receiving ASU required fewer NSAIDs to control symptoms, indicating that ASU exerts both direct analgesic effects and an NSAID-sparing action. This reduction in NSAID use is particularly meaningful in elderly OA populations at risk for gastrointestinal and cardiovascular adverse events [63].

Long-term observational studies further support ASU's effectiveness in real-world practice. Patients maintained on ASU therapy for several years reported sustained symptom control and improved mobility, without evidence of tolerance or diminishing benefit. Unlike intra-articular corticosteroids, which often lose efficacy with repeated administration, ASU appears to maintain consistent effectiveness, reinforcing its suitability for chronic management [64].

Meta-analyses have confirmed these findings. A systematic review pooling data from randomized and observational studies concluded that ASU significantly improves pain and functional outcomes while potentially slowing radiographic progression of OA. The review highlighted the robust safety profile of ASU, with adverse events largely limited to mild gastrointestinal discomfort. Importantly, ASU demonstrated excellent tolerability, with adherence rates superior to those of NSAIDs and comparable to glucosamine/chondroitin [65].

From a clinical pharmacy perspective, these findings highlight ASU as a safe, effective, and sustainable option for long-term OA management. Its demonstrated ability to reduce NSAID use aligns with pharmacotherapeutic goals of minimizing drug-related harm while maintaining quality of life. Furthermore, the structural benefits observed in clinical trials suggest that ASU may occupy a unique role as a nutraceutical with disease-modifying potential, bridging the gap between symptomatic treatments and future regenerative therapies [66].

11. Clinical Evidence for Glucosamine–Chondroitin

Glucosamine and chondroitin sulfate have been extensively investigated in clinical trials over the past two decades, making them among the most studied nutraceuticals in osteoarthritis (OA). Evidence from randomized controlled trials (RCTs) demonstrates that these agents, alone or in combination, provide symptomatic relief and potential structural benefits. The magnitude of clinical response, however, has varied across studies, largely due to differences in study design, patient populations, disease severity, and supplement formulation [67].

One of the landmark studies, the **Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)**, was a multicenter RCT sponsored by the National Institutes of Health (NIH). This trial included over 1,500 patients with knee OA randomized to glucosamine hydrochloride, chondroitin sulfate, the combination, celecoxib, or placebo. The overall population showed no significant improvement with glucosamine, chondroitin, or their combination compared to placebo. However, a prespecified subgroup analysis revealed that patients with **moderate-to-severe knee pain** experienced significant improvement with the glucosamine–chondroitin combination, comparable to celecoxib. This finding suggests that the combination may be particularly beneficial for advanced disease states, while effects in mild OA may be less pronounced [68].

European studies using **pharmaceutical-grade crystalline glucosamine sulfate** and **highly purified chondroitin sulfate** have reported more consistent benefits than studies using dietary supplement formulations. For example, the **MOVES trial**, a large European study comparing glucosamine–chondroitin with celecoxib in knee OA, demonstrated that the nutraceutical combination was non-inferior to celecoxib in reducing WOMAC pain and function scores over six months. This is clinically significant, as it places the glucosamine–chondroitin combination on par with a widely prescribed NSAID, but without the associated gastrointestinal and cardiovascular risks [69].

Long-term structural benefits have also been reported. The **STOPP trial (Study on Osteoarthritis Progression Prevention)** showed that patients treated with chondroitin sulfate alone had less joint space narrowing after two years compared to placebo. Similar findings were observed with glucosamine sulfate in independent studies, suggesting that long-term administration may slow radiographic progression. When used in combination, glucosamine and chondroitin may provide complementary effects on cartilage preservation, supporting their categorization as potential **symptomatic slow-acting drugs for osteoarthritis (SYSADOAs)** [70].

Meta-analyses further support their utility, although results are heterogeneous. Some systematic reviews report moderate but clinically relevant reductions in pain and functional limitations, while others suggest marginal benefit compared to placebo. The variability is likely due to differences in the purity and formulation of tested supplements. Importantly, **pharmaceutical-grade products consistently outperform food supplement-grade products**, highlighting the importance of product

selection in clinical outcomes. This has major implications for clinical pharmacists, who are often consulted by patients self-medicating with over-the-counter products [71].

From a safety standpoint, glucosamine and chondroitin sulfate demonstrate excellent tolerability, with adverse events limited to mild gastrointestinal upset in most cases. They do not carry the cardiovascular, renal, or gastrointestinal risks associated with NSAIDs. This makes them particularly suitable for elderly patients with multiple comorbidities, a population that represents the majority of OA cases. Furthermore, their compatibility with long-term use addresses a critical unmet need in chronic OA management [72].

In conclusion, glucosamine and chondroitin sulfate, particularly in pharmaceutical-grade formulations, have demonstrated efficacy in reducing pain, improving joint function, and potentially slowing structural progression of OA. While heterogeneity in evidence has led to some debate, the weight of high-quality studies suggests that they represent a safe and effective therapeutic option, especially in patients with moderate-to-severe disease or contraindications to NSAIDs. For clinical pharmacists, the challenge lies in ensuring patients receive evidence-based formulations rather than unregulated dietary supplements [73].

12. Comparative Efficacy: ASU vs Glucosamine–Chondroitin

Direct head-to-head randomized controlled trials comparing avocado/soybean unsaponifiables (ASU) with glucosamine–chondroitin sulfate are limited, but indirect evidence from parallel studies allows meaningful comparisons. Both nutraceuticals share important similarities: they are well tolerated, act on multiple pathways involved in osteoarthritis (OA), and are classified as symptomatic slow-acting drugs for osteoarthritis (SYSADOAs). However, their pharmacological profiles and clinical outcomes suggest distinct advantages that may influence treatment selection [74].

One of the main differences lies in the scope of their action. Glucosamine and chondroitin sulfate predominantly target cartilage metabolism. Glucosamine provides substrates for glycosaminoglycan synthesis, while chondroitin inhibits catabolic enzymes and reduces inflammation. In contrast, ASU exerts a broader “whole joint” effect, influencing cartilage, synovium, and subchondral bone. This wider range of activity may explain findings from clinical trials where ASU not only improved pain and function but also slowed radiographic progression in hip OA, an effect less consistently reported for glucosamine–chondroitin [75].

Clinical outcomes further highlight nuanced differences. The GAIT trial demonstrated that glucosamine–chondroitin is particularly effective in patients with moderate-to-severe knee pain, while its benefit in mild OA is less pronounced. Conversely, ASU trials have shown consistent improvements across a wide spectrum of patients, including those with early disease, suggesting it may exert symptomatic benefits regardless of baseline severity. This broader applicability may make ASU more

suitable in early intervention strategies, while glucosamine–chondroitin may be more impactful in advanced disease [76].

Another critical comparison involves NSAID-sparing effects. Both ASU and glucosamine–chondroitin have been shown to reduce NSAID consumption, but ASU appears to demonstrate a stronger and more consistent reduction in trials. This is likely attributable to its anti-inflammatory effects at the synovial level, which directly address pain generation. For pharmacists and clinicians, this translates into improved safety, especially in elderly patients for whom chronic NSAID exposure poses significant risks [77].

When evaluating structural outcomes, the evidence is mixed. ASU has demonstrated radiographic benefit in delaying joint space narrowing in hip OA over three years. Glucosamine and chondroitin sulfate, in high-quality European trials, have also shown evidence of slowing structural progression, particularly with pharmaceutical-grade formulations. However, the heterogeneity of results in glucosamine–chondroitin trials weakens the strength of recommendations compared to ASU, which has produced more consistent radiological outcomes [78].

From a safety and tolerability perspective, both agents perform exceptionally well, with adverse events limited to mild gastrointestinal upset. Unlike NSAIDs, they are safe for use in patients with cardiovascular, renal, or gastrointestinal comorbidities. However, one clinical pharmacy consideration is that glucosamine is derived from shellfish in some formulations, which may limit its use in patients with shellfish allergies or strict dietary restrictions. ASU, being plant-based, avoids these limitations and may be more acceptable to certain patient populations [79].

In summary, both ASU and glucosamine–chondroitin demonstrate meaningful efficacy in OA management, with important differences in clinical application. ASU may be more effective as an early intervention strategy with broader anti-inflammatory benefits, while glucosamine–chondroitin may be particularly suitable for moderate-to-severe cases with established pain and cartilage degradation. For pharmacists, these distinctions provide a framework for tailoring nutraceutical recommendations to individual patient profiles, optimizing outcomes while minimizing unnecessary polypharmacy [80].

13. Safety and Tolerability Profiles

Safety is a critical consideration in osteoarthritis (OA) management, especially since most patients are elderly, frequently have multiple comorbidities, and often require chronic therapy. Both avocado/soybean unsaponifiables (ASU) and glucosamine–chondroitin sulfate combinations have consistently demonstrated excellent safety and tolerability in clinical trials. Unlike NSAIDs or corticosteroids, which carry significant gastrointestinal, cardiovascular, and renal risks, these nutraceuticals provide long-term options without the burden of serious systemic toxicity [81].

For glucosamine, the most commonly reported adverse events are mild gastrointestinal disturbances such as bloating, nausea, or diarrhea. These effects are generally self-limited and rarely require

discontinuation. Concerns about glucosamine's potential impact on glucose metabolism have been raised due to its structural similarity to glucose. However, multiple randomized trials and meta-analyses have shown no clinically significant changes in fasting glucose or HbA1c levels in diabetic patients taking glucosamine sulfate at therapeutic doses. This reassures clinicians and pharmacists that glucosamine is safe even in populations with impaired glycemic control [82].

Chondroitin sulfate is similarly well tolerated, with adverse events limited to mild gastrointestinal upset or, less frequently, allergic skin reactions. Importantly, large pharmacovigilance studies and systematic reviews have shown no increase in major safety events such as cardiovascular complications, renal impairment, or bleeding. This contrasts sharply with NSAIDs, where risks increase substantially with long-term use. From a pharmacist's perspective, this favorable profile allows chondroitin to be recommended with confidence for long-term OA management [83].

Avocado/soybean unsaponifiables (ASU) also demonstrate an excellent safety profile. Across multiple clinical trials, adverse events have been rare and primarily limited to mild gastrointestinal symptoms such as dyspepsia or diarrhea. Importantly, no organ toxicity or clinically significant biochemical abnormalities have been associated with long-term ASU use. In fact, its safety has been confirmed even in studies extending beyond three years, making it one of the most tolerable long-term interventions for OA. The absence of cardiovascular or renal risks further strengthens its role as a safe alternative to NSAIDs in elderly and comorbid patients [84].

Special safety considerations include allergies and drug interactions. Some glucosamine formulations are derived from shellfish, raising concerns for patients with shellfish allergies. However, most reactions reported are mild and related to gastrointestinal intolerance rather than true hypersensitivity. Plant-derived glucosamine alternatives are now available and provide a suitable option for patients with dietary restrictions. Chondroitin sulfate has not been associated with significant drug–drug interactions, though theoretical concerns exist regarding anticoagulant potentiation due to its structural similarity to heparin. Clinical evidence, however, does not support a meaningful risk [85].

Another important safety feature is the NSAID-sparing effect observed with both ASU and glucosamine–chondroitin. By reducing the need for chronic NSAID therapy, these nutraceuticals indirectly enhance safety by lowering the incidence of gastrointestinal bleeding, renal dysfunction, and cardiovascular events. This indirect safety benefit is clinically meaningful, especially in frail populations where adverse drug events are common. From a pharmacist's perspective, recommending nutraceuticals can therefore contribute not only to symptom control but also to safer medication profiles overall [86].

In conclusion, ASU and glucosamine–chondroitin exhibit highly favorable safety and tolerability profiles compared to conventional pharmacotherapy. Adverse events are mild, rare, and self-limiting, with no significant systemic toxicity. Their NSAID-sparing effect enhances safety further, making

them particularly valuable in elderly or comorbid patients who cannot tolerate long-term NSAIDs. Clinical pharmacists should leverage these safety advantages when counseling patients and guiding OA management strategies [87].

Osteoarthritis (OA) continues to represent a major global health challenge due to its high prevalence, progressive nature, and substantial socioeconomic impact. Conventional pharmacological therapies, though effective for short-term symptom relief, fail to modify disease progression and are limited by significant adverse effects with long-term use. This therapeutic gap has driven increasing interest in nutraceuticals with chondroprotective and disease-modifying potential. Among these, glucosamine–chondroitin sulfate and avocado/soybean unsaponifiables (ASU) have emerged as two of the most promising options.

Glucosamine and chondroitin sulfate, particularly in pharmaceutical-grade formulations, have demonstrated consistent benefits in pain reduction, functional improvement, and, in select studies, slowing of radiographic disease progression. Their combined use capitalizes on complementary mechanisms, with glucosamine primarily supporting anabolic cartilage repair and chondroitin exerting anti-catabolic and anti-inflammatory effects. The evidence suggests particular efficacy in patients with moderate-to-severe disease, where the combination may rival NSAIDs in symptomatic improvement but without associated systemic risks.

Avocado/soybean unsaponifiables, by contrast, demonstrate broader “whole joint” activity, targeting not only cartilage metabolism but also synovial inflammation and subchondral bone remodeling. Clinical trials have shown consistent reductions in pain and functional limitations, coupled with an NSAID-sparing effect and, importantly, evidence of delayed joint space narrowing. ASU’s consistent safety, tolerability, and applicability across various stages of OA make it a compelling alternative or adjunct to glucosamine–chondroitin.

From a clinical pharmacy perspective, the practical implications are clear. Both nutraceutical strategies provide safe, long-term options that can be tailored to individual patient needs. Product quality and standardization remain critical, as only pharmaceutical-grade preparations have consistently demonstrated clinical efficacy. Pharmacists play a central role in counseling patients on appropriate product selection, adherence, and monitoring, particularly given the widespread availability of variable-quality dietary supplements. Additionally, these agents reduce reliance on NSAIDs, thereby indirectly enhancing safety in elderly and comorbid populations.

Despite promising evidence, several gaps remain. Head-to-head comparative trials between ASU and glucosamine–chondroitin are scarce, and further large-scale, long-term studies are needed to establish relative superiority, optimal dosing regimens, and potential synergistic use. Future research should also evaluate pharmacoeconomic outcomes, as nutraceuticals may reduce long-term healthcare costs by delaying surgical interventions and lowering reliance on conventional analgesics.

In conclusion, both glucosamine–chondroitin sulfate and ASU represent viable, evidence-based nutraceuticals with demonstrated chondroprotective and symptomatic benefits in OA management. While glucosamine–chondroitin has stronger historical evidence and proven efficacy in moderate-to-severe disease, ASU offers broader mechanisms and more consistent long-term outcomes, especially in reducing structural progression and NSAID use. Incorporating these agents into OA treatment algorithms represents a rational, patient-centered approach, with clinical pharmacists playing a pivotal role in guiding safe, effective, and evidence-based utilization.

REFERENCES

1. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. *Lancet*. 2019;393(10182):1745-1759.
2. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. *Osteoarthritis Cartilage*. 2019;27(11):1578-1589.
3. Reginster JY, Veronese N. Glucosamine and chondroitin sulfate in osteoarthritis: pharmacological and clinical evidence. *Drugs Aging*. 2021;38(10):867-882.
4. Wandel S, Jüni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. *BMJ*. 2010;341:c4675.
5. Henrotin Y, Lambert C. Avocado/soybean unsaponifiables: a review of their effects on osteoarthritis symptoms and progression. *J Evid Based Complementary Altern Med*. 2013;18(1):25-30.
6. Maheu E, Bannuru RR, Herrero-Beaumont G, et al. Why we should definitely include avocado/soybean unsaponifiables in the management of osteoarthritis. *Joint Bone Spine*. 2019;86(6):647-649.
7. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396(10258):1204-1222.
8. Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study. *Ann Rheum Dis*. 2014;73(7):1323-1330.
9. Hunter DJ, March L, Chew M. Osteoarthritis in 2020 and beyond: a Lancet Commission. *Lancet*. 2020;396(10264):1711-1712.
10. Bliddal H, Leeds AR, Christensen R. Osteoarthritis, obesity and weight loss: evidence, hypotheses and horizons – a scoping review. *Obes Rev*. 2014;15(7):578-586.
11. Palazzo C, Nguyen C, Lefevre-Colau MM, Rannou F, Poiraudou S. Risk factors and burden of osteoarthritis. *Ann Phys Rehabil Med*. 2016;59(3):134-138.
12. Martel-Pelletier J, Barr AJ, Cicuttini FM, et al. Osteoarthritis. *Nat Rev Dis Primers*. 2016;2:16072.
13. Malemud CJ. Biologic basis of osteoarthritis: state of the evidence. *Curr Opin Rheumatol*. 2015;27(3):289-294.
14. Goldring MB, Goldring SR. Osteoarthritis. *J Cell Physiol*. 2007;213(3):626-634.
15. Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. *Nat Rev Rheumatol*. 2010;6(11):625-635.
16. Francisco V, Pérez T, Pino J, et al. Biomechanics, obesity, and osteoarthritis. The role of adipokines: when the levee breaks. *J Orthop Res*. 2018;36(2):594-604.
17. Henrotin Y, Lambert C, Richette P. Importance of synovitis in osteoarthritis: evidence for the use of glycosaminoglycans against synovial inflammation. *Semin Arthritis Rheum*. 2014;43(5):579-587.
18. Fernandes L, Hagen KB, Bijlsma JW, et al. EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. *Ann Rheum Dis*. 2013;72(7):1125-1135.
19. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of NSAIDs: meta-analyses of individual participant data from randomised trials. *Lancet*. 2013;382(9894):769-779.
20. Machado GC, Maher CG, Ferreira PH, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. *BMJ*. 2015;350:h1225.

21. McAlindon TE, LaValley MP, Harvey WF, et al. Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. *JAMA*. 2017;317(19):1967-1975.
22. Jevsevar DS. Treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition. *J Am Acad Orthop Surg*. 2013;21(9):571-576.
23. Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Chondroitin for osteoarthritis. *Cochrane Database Syst Rev*. 2015;(1):CD005614.
24. Honvo G, Reginster JY, Rabenda V, Geerinck A, Mkinsi O, Bruyère O. Safety of symptomatic slow-acting drugs for osteoarthritis: outcomes of a systematic review and meta-analysis. *Drugs Aging*. 2019;36(Suppl 1):65-99.
25. Bruyère O, Cooper C, Al-Daghri N, et al. Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). *Aging Clin Exp Res*. 2018;30(2):111-117.
26. Henrotin Y, Sanchez C, Balligand M. Pharmaceutical and nutraceutical management of osteoarthritis: current knowledge and future trends. *Drugs Aging*. 2005;22(10):1-20.
27. Maheu E, Bannuru RR, Herrero-Beaumont G, Allali F, Bardin T. Why we should definitely include avocado/soybean unsaponifiables in the management of osteoarthritis. *Joint Bone Spine*. 2019;86(6):647-649.
28. Reginster JY, Dudler J, Blicharski T, Pavelka K. Pharmaceutical-grade glucosamine sulfate in the treatment of osteoarthritis: evidence from clinical trials and pharmacokinetic studies. *Ther Adv Musculoskelet Dis*. 2021;13:1759720X20978347.
29. Henrotin Y, Lambert C. Avocado/soybean unsaponifiables: a review of their effects on osteoarthritis symptoms and progression. *J Evid Based Complementary Altern Med*. 2013;18(1):25-30.
30. Largo R, Alvarez-Soria MA, Díez-Ortego I, et al. Glucosamine inhibits IL-1 β -induced NF κ B activation in human chondrocytes. *Osteoarthritis Cartilage*. 2003;11(4):290-298.
31. Calamia V, Fernández-Puente P, Mateos J, et al. Pharmacoproteomic study of the effects of glucosamine sulfate on human chondrocytes. *Arthritis Res Ther*. 2010;12(4):R138.
32. Herrero-Beaumont G, Roman-Blas JA, Castañeda S, Jimenez SA. Primary osteoarthritis no longer primary: three subsets with distinct etiological, clinical, and therapeutic characteristics. *Semin Arthritis Rheum*. 2009;39(2):71-80.
33. Persiani S, Roda E, Rovati LC, et al. Glucosamine oral bioavailability and pharmacokinetics after single doses of crystalline glucosamine sulfate in man. *Osteoarthritis Cartilage*. 2005;13(12):1041-1049.
34. Hua J, Suguro S, Hirano S, et al. Glucosamine suppresses interleukin-1 β -mediated activation of nuclear factor- κ B and p38 mitogen-activated protein kinase in human chondrocytes. *Arthritis Rheum*. 2007;56(1):153-162.
35. Reginster JY, Dudler J, Blicharski T, Pavelka K. Pharmaceutical-grade glucosamine sulfate in the treatment of osteoarthritis: evidence from clinical trials and pharmacokinetic studies. *Ther Adv Musculoskelet Dis*. 2021;13:1759720X20978347.
36. Volpi N. Chondroitin sulfate safety and quality. *Molecules*. 2019;24(8):1447.
37. Uebelhart D, Thonar EJ, Delmas PD, Chantraine A, Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. *Osteoarthritis Cartilage*. 1998;6(Suppl A):39-46.
38. Chan PS, Caron JP, Orth MW. Effect of glucosamine and chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine articular cartilage explants. *Am J Vet Res*. 2005;66(11):1870-1876.
39. Tat SK, Pelletier JP, Vergés J, et al. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. *Arthritis Res Ther*. 2007;9(6):R117.
40. Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of chondroitin sulfate. *Osteoarthritis Cartilage*. 1998;6(Suppl A):14-21.
41. Henrotin Y, Marty M, Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? *Maturitas*. 2014;78(3):184-187.
42. Hochberg MC. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials. *Osteoarthritis Cartilage*. 2010;18(Suppl 1):S28-S31.
43. Martel-Pelletier J, Roubille C, Abram F, et al. First-line analysis of the effects of glucosamine and chondroitin sulfate in patients with osteoarthritis: a systematic review and meta-analysis. *Drugs Aging*. 2015;32(7):531-540.
44. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. *N Engl J Med*. 2006;354(8):795-808.
45. Kahan A, Uebelhart D, De Vathaire F, et al. Long-term effects of chondroitin sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention (STOPP). *Arthritis Rheum*. 2009;60(2):524-533.
46. Wandel S, Jüni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. *BMJ*. 2010;341:c4675.
47. Reginster JY, Veronese N. Highly purified chondroitin sulfate: a literature review on clinical efficacy and safety in osteoarthritis. *Int J Mol Sci*. 2021;22(3):1057.
48. Roman-Blas JA, Mediero A, Tardio L, Largo R, Herrero-Beaumont G. The combination of chondroitin sulfate and glucosamine sulfate shows anti-inflammatory and chondroprotective effects in human osteoarthritic synovial fibroblasts in vitro. *Eur J Pharmacol*. 2017;794:8-14.

49. Henrotin Y, Lambert C. Avocado/soybean unsaponifiables: a review of their effects on osteoarthritis symptoms and progression. *J Evid Based Complementary Altern Med*. 2013;18(1):25-30.
50. Au RY, Al-Talib TK, Au AY, Phan PV, Frondoza CG. Avocado soybean unsaponifiables (ASU) suppress TNF- α , IL-1 β , COX-2, iNOS gene expression, and prostaglandin E2 and nitric oxide production in articular chondrocytes and monocyte/macrophages. *Osteoarthritis Cartilage*. 2007;15(11):1249-1255.
51. Boumediene K, Felisaz N, Bogdanowicz P, Galera P, Guillou GB, Pujol JP. Avocado/soybean unsaponifiables enhance the expression of transforming growth factor beta1 and beta2 in cultured articular chondrocytes. *Arthritis Rheum*. 1999;42(1):148-156.
52. Henrotin Y, Priem F, Mobasheri A. Curcumin: a new paradigm and therapeutic opportunity for the treatment of osteoarthritis: curcumin for osteoarthritis management. *Springerplus*. 2013;2:56.
53. Boileau C, Martel-Pelletier J, Caron J, et al. Protective effects of total fraction of avocado/soybean unsaponifiables on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and matrix metalloproteinase-13. *Arthritis Res Ther*. 2009;11(2):R41.
54. Maheu E, Bannuru RR, Herrero-Beaumont G, et al. Why we should definitely include avocado/soybean unsaponifiables in the management of osteoarthritis. *Joint Bone Spine*. 2019;86(6):647-649.
55. Altinel L, Saritas ZK, Kaptan AY, et al. Effects of avocado/soybean unsaponifiables on osteoarthritis in a rabbit model. *Clin Rheumatol*. 2007;26(9):1371-1378.
56. Henrotin Y, Sanchez C, Deberg MA, et al. Avocado/soybean unsaponifiables upregulate expression of transforming growth factor beta in human articular chondrocytes. *Arthritis Rheum*. 2003;48(12):3704-3711.
57. Au RY, Al-Talib TK, Au AY, Phan PV, Frondoza CG. Avocado soybean unsaponifiables (ASU) suppress TNF- α , IL-1 β , COX-2, iNOS gene expression, and prostaglandin E2 and nitric oxide production in articular chondrocytes and monocyte/macrophages. *Osteoarthritis Cartilage*. 2007;15(11):1249-1255.
58. Boileau C, Martel-Pelletier J, Caron J, et al. Protective effects of total fraction of avocado/soybean unsaponifiables on structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and matrix metalloproteinase-13. *Arthritis Res Ther*. 2009;11(2):R41.
59. Tat SK, Pelletier JP, Vergés J, et al. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. *Arthritis Res Ther*. 2007;9(6):R117.
60. Henrotin Y, Lambert C. Avocado/soybean unsaponifiables: a review of preclinical mechanisms. *J Evid Based Complementary Altern Med*. 2013;18(1):25-30.
61. Appelboom T, Schuermans J, Verbruggen G, Henrotin Y, Reginster JY. Symptoms modifying effect of avocado/soybean unsaponifiables in knee osteoarthritis: a double-blind, placebo-controlled trial. *Scand J Rheumatol*. 2001;30(4):242-247.
62. Maheu E, Mazières B, Valat JP, et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial. *Arthritis Rheum*. 1998;41(1):81-91.
63. Blotman F, Maheu E, Wulwik A, Caspard H, Lopez A. Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. *Rev Rhum Engl Ed*. 1997;64(12):825-834.
64. Lequesne M, Maheu E, Cadet C, Dreiser RL. Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. *Arthritis Rheum*. 2002;47(1):50-58.
65. Christensen R, Bartels EM, Astrup A, Bliddal H. Avocado-soybean unsaponifiables (ASU) for osteoarthritis: a systematic review and meta-analysis. *Osteoarthritis Cartilage*. 2008;16(4):399-408.
66. Maheu E, Bannuru RR, Herrero-Beaumont G, et al. Why we should definitely include avocado/soybean unsaponifiables in the management of osteoarthritis. *Joint Bone Spine*. 2019;86(6):647-649.
67. Reginster JY, Veronese N. Glucosamine and chondroitin sulfate in osteoarthritis: pharmacological and clinical evidence. *Drugs Aging*. 2021;38(10):867-882.
68. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. *N Engl J Med*. 2006;354(8):795-808.
69. Herrero-Beaumont G, Román JA, Trabado MC, et al. Glucosamine sulfate and chondroitin sulfate in knee osteoarthritis: a double-blind, non-inferiority, randomized controlled trial (MOVES). *Ann Rheum Dis*. 2015;74(6):985-991.
70. Kahan A, Uebelhart D, De Vathaire F, et al. Long-term effects of chondroitin sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention (STOPP). *Arthritis Rheum*. 2009;60(2):524-533.
71. Wandel S, Jüni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. *BMJ*. 2010;341:c4675.
72. Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. *Cochrane Database Syst Rev*. 2009;(2):CD002946.
73. Reginster JY, Dudler J, Blicharski T, Pavelka K. Pharmaceutical-grade glucosamine sulfate and chondroitin sulfate in the management of osteoarthritis: an updated evidence-based review. *Adv Ther*. 2021;38(7):3463-3483.
74. Henrotin Y, Marty M, Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? *Maturitas*. 2014;78(3):184-187.
75. Lequesne M, Maheu E, Cadet C, Dreiser RL. Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. *Arthritis Rheum*. 2002;47(1):50-58.

76. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. *N Engl J Med*. 2006;354(8):795-808.
77. Blotman F, Maheu E, Wulwik A, Caspard H, Lopez A. Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. *Rev Rhum Engl Ed*. 1997;64(12):825-834.
78. Kahan A, Uebelhart D, De Vathaire F, et al. Long-term effects of chondroitin sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention (STOPP). *Arthritis Rheum*. 2009;60(2):524-533.
79. Reginster JY, Dudler J, Blicharski T, Pavelka K. Pharmaceutical-grade glucosamine sulfate and chondroitin sulfate in the management of osteoarthritis: an updated evidence-based review. *Adv Ther*. 2021;38(7):3463-3483.
80. Maheu E, Bannuru RR, Herrero-Beaumont G, et al. Why we should definitely include avocado/soybean unsaponifiables in the management of osteoarthritis. *Joint Bone Spine*. 2019;86(6):647-649.
81. Honvo G, Reginster JY, Rabenda V, Geerinck A, Mkinsi O, Bruyère O. Safety of symptomatic slow-acting drugs for osteoarthritis: outcomes of a systematic review and meta-analysis. *Drugs Aging*. 2019;36(Suppl 1):65-99.
82. Dostrovsky NR, Towheed TE, Hudson RW, Anastassiades TP. The effect of glucosamine on glucose metabolism in humans: a systematic review of the literature. *Osteoarthritis Cartilage*. 2011;19(4):375-380.
83. Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Chondroitin for osteoarthritis. *Cochrane Database Syst Rev*. 2015;(1):CD005614.
84. Maheu E, Cadet C, Marty M, Moysse D, Kerloch I, Coste P. Randomised, controlled trial of avocado–soybean unsaponifiables in the treatment of hip osteoarthritis: three years’ follow-up. *Arthritis Care Res*. 2014;66(11):1704-1711.
85. Volpi N. Quality of different chondroitin sulfate preparations in relation to their therapeutic activity. *J Pharm Pharmacol*. 2009;61(10):1271-1280.
86. Blotman F, Maheu E, Wulwik A, Caspard H, Lopez A. Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. *Rev Rhum Engl Ed*. 1997;64(12):825-834.
87. Reginster JY, Veronese N. Highly purified chondroitin sulfate and glucosamine sulfate: safety evidence from clinical use. *Int J Mol Sci*. 2021;22(3):1057.